CytRx begins Phase II pancreatic ductual adenocarcinomas trial
The open-label Phase II clinical trial will evaluate the preliminary efficacy and safety of INNO-206 in pancreatic cancer. The patients enrolled in the trial will be treated with
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.